Oppenheimer Asset Management Inc. Buys Shares of 111,624 Gilead Sciences, Inc. $GILD

Oppenheimer Asset Management Inc. purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 111,624 shares of the biopharmaceutical company’s stock, valued at approximately $14,103,000.

Several other hedge funds have also made changes to their positions in GILD. Aviva PLC boosted its position in shares of Gilead Sciences by 5.4% during the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after buying an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd acquired a new stake in Gilead Sciences in the 4th quarter valued at approximately $1,418,000. NBC Securities Inc. raised its stake in Gilead Sciences by 150.3% during the 4th quarter. NBC Securities Inc. now owns 17,147 shares of the biopharmaceutical company’s stock valued at $2,105,000 after acquiring an additional 10,296 shares in the last quarter. Flputnam Investment Management Co. raised its stake in Gilead Sciences by 66.5% during the 4th quarter. Flputnam Investment Management Co. now owns 105,740 shares of the biopharmaceutical company’s stock valued at $12,978,000 after acquiring an additional 42,243 shares in the last quarter. Finally, Harvest Fund Management Co. Ltd boosted its position in Gilead Sciences by 14.4% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock worth $13,075,000 after acquiring an additional 13,385 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on GILD shares. Rothschild & Co Redburn decreased their price target on Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a report on Wednesday, August 5th. Weiss Ratings lowered shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 target price on shares of Gilead Sciences in a research note on Wednesday, August 5th. Finally, Truist Financial dropped their price target on shares of Gilead Sciences from $157.00 to $156.00 and set a “buy” rating on the stock in a research report on Tuesday, July 7th. Twenty-four research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Stock Up 0.2%

Shares of NASDAQ:GILD opened at $138.36 on Friday. The firm has a 50 day simple moving average of $130.11 and a 200 day simple moving average of $136.45. Gilead Sciences, Inc. has a 52 week low of $108.46 and a 52 week high of $157.29. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The company has a market cap of $171.56 billion, a PE ratio of -51.82 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm had revenue of $7.80 billion for the quarter, compared to analysts’ expectations of $7.40 billion. During the same period in the previous year, the company posted $2.01 EPS. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, research analysts expect that Gilead Sciences, Inc. will post -0.53 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be issued a dividend of $0.82 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.4%. Gilead Sciences’s payout ratio is currently -122.85%.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Appeals court ruling protects Gilead’s distribution channels. A U.S. appeals court upheld an injunction preventing alternative funding programs and related businesses from importing Gilead medications overseas. The decision could reduce the size of the alternative funding industry and help protect Gilead’s pricing, sales channels and patient-assistance economics. Court rules companies can’t import Gilead medications from overseas in blow to AFP health programs
• Positive Sentiment: Q2 growth highlighted continued commercial momentum. Gilead’s HIV franchise led year-over-year sales growth, with Biktarvy and PrEP performing particularly well. Quarterly PrEP sales reportedly doubled to more than $1 billion, while Trodelvy, Livdelzi and progress in oncology and liver disease added to the growth outlook. 5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call
• Positive Sentiment: AI collaboration strengthens the oncology pipeline. Gilead partnered with Nucleai to use AI-powered tissue analytics in its antibody-drug-conjugate programs. The technology is intended to accelerate biomarker discovery and improve precision-oncology development. Gilead Sciences Expands ADC Research With AI Tissue Analytics
• Positive Sentiment: Merck partnership offers longer-term growth potential. Recent clinical and regulatory progress involving Gilead and Merck’s collaboration reinforces the possibility that the partnership could produce meaningful future growth in areas such as oncology and infectious disease. Could Merck and Gilead’s Partnership Create the Next Big Pharma Growth Engine
• Neutral Sentiment: Analysts and investors continue to debate whether Gilead remains attractively valued after its strong multiyear performance. High call-option activity signals bullish positioning but does not guarantee sustained gains.
• Negative Sentiment: An analyst reduced the FY2026 EPS forecast, potentially reflecting concerns about earnings normalization, expenses or pipeline investment. The revision may limit near-term upside despite Gilead’s solid revenue trends. FY2026 EPS Forecast for Gilead Sciences Reduced by Analyst

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $125.40, for a total transaction of $376,200.00. Following the completion of the sale, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $131.46, for a total value of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 51,000 shares of company stock worth $6,568,860. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.